Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

Prostate Cancer Treatment

Types of PSA Test

Prostate Cancer and Diet

Prostate Cancer Epidemiology Worldwide

What is Prostatitis?

What is the PCA3 Test?

Differentiating between prostate cancer and prostate enlargement

What Should You Avoid Before a PSA Test?

What is Prostatectomy?

Hormonal therapy for prostate cancer

Recent Genetic Breakthroughs in Prostate Cancer Research

See more featured articles »

Prostate Cancer Symptoms

Prostate cancer prevention

What is benign prostatic hyperplasia?

Brachytherapy for Prostate Cancer

Prostatitis symptoms

Single Nucleotide Polymorphisms and Prostate Cancer

Survival rates of prostate cancer

Radiation therapy for prostate cancer

What is the Gleason Score?

The International Prostate Symptoms Score (IPSS)

Prostate Cancer Cell Dormancy and Activation

Should MRI be Used to Diagnose Prostate Cancer?

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Causes of benign prostatic hyperplasia

Prostate Cancer Partin Tables

Choosing the best treatment of prostate cancer - by stage

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Diagnosis of prostatitis

Symptoms of Benign Prostatic Hyperplasia (BHP)

Prostate Cancer Staging

What is TURP?

Palliative treatment and end of life care for prostate cancer

Prostate Cancer Questions

Prostate Biopsy

Life after prostate cancer treatment

Causes of prostatitis

Prostate Cancer Risk Factors

Prostate Cancer Diagnosis

Precancerous conditions of the prostate

What is medical castration?

Vasectomy and prostate cancer: Myth or reality?

PSA False Positive and False Negative Results

Prostate Cancer Epidemiology

Prostate Cancer Screening

Cryosurgery for prostate cancer

Gold Nanoparticles Use in Prostate Cancer

Prostate Cancer Research

Prostate cancer complications

Prostate Cancer and Genetics

Prostate Cancer and Exercise

Treatment of Benign Prostatic Hyperplasia (BHP)

The Prostate

Breakthroughs in Prostate Cancer Treatments

Rectal Examination for Prostate Cancer

Can Curcumin Prevent or Treat Prostate Cancer?

Treatment of prostatitis

Prostate cancer alternative and complementary therapies

What is the PSA Test?

PSA Test in Men Who Have Been Treated for Prostate Cancer

Latest Prostate Cancer News and Research

Tailoring prostate cancer radiotherapy to body clock could cut long-term side effects

A study by Leicester researchers shows that the timing of radiotherapy treatment may be as important as how it is given for prostate cancer patients.

30 Oct 2026

Updated ASTRO guidelines recommend shorter radiation courses for prostate cancer

An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer.

27 Oct 2026

Study establishes new perioperative standard in prostate cancer

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide - a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.

27 Oct 2026

New alpha-emitting radiopharmaceutical therapy achieves strong responses in advanced prostate cancer

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a phase 1 trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track.

26 Oct 2026

Study reveals a broad shift away from overtreatment of low-risk prostate cancer

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer.

26 Oct 2026

Clues to prostate cancer risk in blood samples taken 15 years earlier

Recent study links blood proteins to aggressive prostate cancer, identifying potential biomarkers for early risk prediction and insights into immune activity.

26 Oct 2026

Abiraterone triplet therapy improves long-term survival in metastatic prostate cancer

Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification.

24 Oct 2026

Decipher tissue-based molecular test helps personalize high-risk prostate cancer treatment

Prostate cancer is the most common cancer in men – in 2013, it affected more than one million men across the world.

23 Oct 2026

Study identifies blood proteins associated with aggressive prostate cancer risk

Proteins linked to the immune system, cell adhesion, blood vessel formation and known prostate cancer genes, were associated with the future risk of developing prostate cancer, including aggressive disease, in a new study led by researchers at Oxford Population Health.

21 Oct 2026

Discovery of new bacteria opens fresh avenues for prostate cancer research

University of East Anglia researchers have discovered the genetic blueprints of 18 new bacterial species collected from prostate cancer patients.

20 Oct 2026

New review highlights expanding potential of therapeutic DNA vaccines

A new review published in Genes & Diseases highlights the expanding potential of DNA-based vaccines as a flexible platform for preventing infectious diseases, treating cancer and strengthening preparedness for future disease outbreaks.

12 Oct 2026

US counties with more medical debt see higher rates of several late-stage cancers

Higher medical debt is linked to more late-stage cancer diagnoses across U.S. counties.

9 Oct 2026

NCCN collaborates with global organizations to launch tailored cancer guidelines for Philippines

The National Comprehensive Cancer Network (NCCN)-an alliance of leading academic cancer centers in the United States-is collaborating with several global organizations to publish new International Adaptations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the Philippines.

8 Oct 2026

Single tRNA controls prostate cancer identity and treatment resistance

Researchers at Fred Hutch Cancer Center have identified a previously overlooked molecular regulator that helps determine whether prostate tumors remain sensitive to treatment or evolve into a more aggressive, drug-resistant form of the disease.

7 Oct 2026

NCCN summit highlights strategies to improve cancer prevention and screening

The National Comprehensive Cancer Network (NCCN) hosted a two-day summit focused on expanding access to life-saving cancer prevention and screening.

6 Oct 2026

Experimental cancer drug works differently than researchers originally thought

A cancer drug currently being tested in patients may have entered clinical trials based on an incorrect understanding of how it works, according to a new study led by the University of Sydney in collaboration with Goethe University, Oxford University and the Institute of Cancer Research, London.

6 Oct 2026

Simple urine test can accurately diagnose and track bladder cancer

A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose people with bladder cancer more accurately than current standard methods.

5 Oct 2026

Five-treatment radiation provides excellent long-term prostate cancer control

Five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control with fewer urinary and sexual side effects than surgery in the first randomized trial to directly compare the treatments for localized prostate cancer.

28 Sep 2026

Prostate cancer biology helps identify hormone therapy candidates

A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic classifier to determine whether tumor biology could help identify patients most likely to benefit from hormone therapy.

27 Sep 2026

$Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes$

Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes

Men with high-risk prostate cancer have a higher likelihood of having residual disease following prostatectomy and may require radiation therapy after surgery, particularly when PSA levels begin to rise. Conventional postprostatectomy radiotherapy (COPORT) is typically delivered over 37 fractions, while hypofractionated postprostatectomy radiotherapy (HYPORT) delivers a slightly lower total radiation dose over just 25 fractions.

27 Sep 2026